Craig Hallum Lowers Exagen (NASDAQ:XGN) Price Target to $10.00

Exagen (NASDAQ:XGN) had its price target dropped by research analysts at Craig Hallum from $12.00 to $10.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price objective indicates a potential upside of 212.11% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. B. Riley Financial reaffirmed a “buy” rating and issued a $8.00 target price (down from $18.00) on shares of Exagen in a report on Friday, January 30th. William Blair reissued an “outperform” rating on shares of Exagen in a research note on Tuesday. TD Cowen reduced their price target on Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, February 24th. KeyCorp lowered their price objective on Exagen from $15.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, BTIG Research dropped their price objective on shares of Exagen from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Exagen currently has an average rating of “Moderate Buy” and a consensus target price of $10.29.

Exagen Price Performance

Exagen stock traded down $0.05 during mid-day trading on Wednesday, reaching $3.20. The company had a trading volume of 61,152 shares, compared to its average volume of 518,347. The business has a fifty day simple moving average of $4.24 and a 200 day simple moving average of $7.53. The company has a market cap of $72.60 million, a P/E ratio of -3.48 and a beta of 1.88. Exagen has a fifty-two week low of $2.91 and a fifty-two week high of $12.23. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 1.35.

Exagen (NASDAQ:XGN) last announced its quarterly earnings results on Tuesday, March 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). Exagen had a negative net margin of 29.94% and a negative return on equity of 113.48%. The company had revenue of $16.63 million during the quarter, compared to the consensus estimate of $16.46 million. On average, equities research analysts predict that Exagen will post -0.88 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO John Aballi sold 15,698 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $3.62, for a total value of $56,826.76. Following the completion of the sale, the chief executive officer directly owned 687,299 shares in the company, valued at $2,488,022.38. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Exagen

Several institutional investors and hedge funds have recently made changes to their positions in XGN. Acadian Asset Management LLC acquired a new stake in shares of Exagen in the first quarter valued at about $25,000. Truvestments Capital LLC lifted its stake in shares of Exagen by 109.5% in the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock worth $38,000 after acquiring an additional 3,225 shares during the period. Persistent Asset Partners Ltd acquired a new position in shares of Exagen in the fourth quarter worth approximately $80,000. Schonfeld Strategic Advisors LLC bought a new stake in Exagen in the fourth quarter valued at approximately $82,000. Finally, Jain Global LLC bought a new stake in Exagen in the fourth quarter valued at approximately $82,000. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen News Summary

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Record revenue and test‑volume growth — Exagen reported strong Q4 and full‑year 2025 results, with record total revenue, higher AVISE CTD average selling price and >11% year‑over‑year test volume growth, supporting commercial momentum. Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
• Positive Sentiment: Analyst support remains — BTIG lowered its price target from $10 to $9 but maintained a “buy” rating, implying significant upside from current levels and signaling continued analyst conviction in the growth story. Exagen (XGN) PT Lowered to $9 at BTIG
• Positive Sentiment: Commercial investment ramp — Management highlighted expansion of the sales force and an accelerated innovation cadence as drivers for 2026 growth, which could support higher ASPs and incremental test volume over time. Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence
• Neutral Sentiment: Q4 earnings in line — EPS loss of ($0.20) matched consensus while revenue of $16.63M modestly beat estimates, leaving profitability progress largely unchanged in the near term. Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
• Neutral Sentiment: Earnings materials available — The company posted its earnings release, slide deck and the full call transcript for investors who want detail on commercial cadence and margin targets. Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: FY‑2026 revenue guide misses consensus — Management guided revenue of $70.0M–$73.0M for 2026 versus a roughly $74M consensus, a modest shortfall that likely prompted some of the intra‑day selling pressure. Press Release / Slide Deck
• Negative Sentiment: Short interest rising — Short interest increased ~21% in February to roughly 1.07M shares (~5.4% of float) with a ~4‑day days‑to‑cover, indicating growing bearish positioning that can amplify downside on weak news or liquidity events.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.